Articles by Cynthia Challener, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Cynthia Challener, PhD

Cynthia Challener, PhD


Articles
CPhI 2014 Highlights
November 17, 2014

Selected new technologies, products, and facilities from CPhI Worldwide 2014 are reviewed.

Advances in Large-Scale Heterocyclic Synthesis
November 2, 2014

New practical approaches to the synthesis of complex heterocycles are reviewed.

Parenterals, Particulates, and Quality by Design
November 2, 2014

The parenteral manufacturing industry is taking action to address particulate contamination issues.

DoE Provides Benefits, but Preparation Is Necessary
November 2, 2014

Defining critical parameters and processing large quantities of data can be a challenge.

Mission: Close Gaps in the Supply Chain
November 1, 2014

Supply chain security and quality group Rx-360 driven by patient safety.

GMP Fluorination Challenges Limit Use in API Synthesis
November 1, 2014

Fluorination can significantly impact the bioavailability of drug substances, however, safer fluorinating reagents and access to GMP fluorination capabilities remain challenges.

Change is Afoot at CPhI
October 8, 2014

New investments, expansions, and company rebranding are discussed at CPhI.

CMO Consolidation Continues
October 6, 2014

The last 12 months have seen a number of major acquisitions in the contract manufacturing space.

Focus on Biosimilars
October 6, 2014

The total market for biopharmaceuticals in 2013 was $36.8 billion according to Kalorama Information. Meanwhile, Frost & Sullivan estimates that the biosimilars market, which it pegged at just $1.2 billion in 2013, will grow to $23 billion in 2019, or more than 20-fold increase.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here